Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Ovarian Cancer
Interventions
PROCEDURE

Secondary cytoreduction

Repeated tumor cell reduction surgery for recurrent ovarian cancer patients

DRUG

Hyperthermic intraperitoneal chemotherapy

Using the BR-TQR-I intraperitoneal hyperthermic perfusion chemotherapy instrument, after the surgical operation is completed, four drainage tubes are placed in the left and right upper abdomen and lower abdomen respectively. Connect all pipelines and preheat the instrument before starting treatment. The treatment temperature is controlled at 43 ℃± 0.1 ℃, the treatment time is 90 minutes, and the circulation pump flow rate is 400-600ml/min. Within 48 hours after the surgery, cisplatin 75mg/㎡ was added to 3000ml of physiological saline for intraperitoneal hot infusion. Through the comprehensive effects of circulation flushing, hyperthermia, chemotherapy, and thermochemotherapy sensitization, it kills and removes residual cancer cells or small lesions in the abdominal cavity.

Trial Locations (1)

200032

Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER